Gus Cairns Editor

Gus joined the editorial team in 2009 and has previously edited HIV Treatment Update and Preventing HIV. He currently focuses on the PrEP in Europe Initiative and on news reporting.

Diagnosing children

Finding the missing children: paediatric index testing expands in Africa

PrEP programmes & uptake

Many people in African PrEP programmes stop and restart PrEP

PrEP science

A second study finds introducing PrEP to Africa considerably reduces HIV infections in women

Child developmental issues

Aged five, uninfected children of HIV-positive mothers do just as well as children of HIV-negative mothers, South African study shows

PrEP science

Injectable PrEP offers superior efficacy to oral PrEP in clinical trial

The search for a cure

Has someone been cured of HIV with a cheap, simple drug regimen?

PrEP programmes & uptake

At least 28,000 women in the United States have started PrEP

PrEP science

PrEP prevents an estimated three-quarters of HIV infections in people at risk in large African study

PrEP science

PrEP and drug resistance

UK health services

Walk-in STI services may be a thing of the past as UK clinics continue to adjust to COVID-19

PEP

HIV 'morning-after pill' prescriptions have fallen sixfold during the lockdown

PrEP science

Seventy per cent fewer HIV infections seen with PrEP injections, compared with pills, in gay/bi men and trans women

Health services & systems

Disruption to HIV treatment in Africa during COVID-19 pandemic could double HIV deaths, modelling studies warn

Cardiovascular disease

People switching from TDF to TAF experience rising cholesterol levels

Mental & emotional health & wellbeing

Stigma and negativity from within the community increases HIV risk-taking by gay men

Sexually transmitted infections tests & treatment

UK sexual health services are being decimated by COVID-19

The search for an HIV prevention vaccine

HIV prevention trials paused during coronavirus crisis

Retention & linkage to care

US emergency department testing finds a lot of people with new – and returning – HIV infections